Navigation Links
Angiotensin-II-receptor blockers - Treat kidney failure

Drugs used to treat high blood pressure have been found to also help slow the progress of kidney failure. Three separate drug trials reveal that the angiotensin-II-receptor blockers, which include losartan and irbesartan, can be used to treat kidney failure, one of the commonest complications in diabetes. //

In the first trial, carried out by doctors in Boston, USA, 1500 patients with type 2 diabetes and kidney disease were given either losartan or placebo. After three years of follow up, the losartan group had a 28 per cent lower risk of end-stage kidney disease. This is equivalent to delaying the need for dialysis or transplantation by two years.

The second trial involved researchers in Chicago who found that the progression of kidney disease or death was reduced by around 20 per cent in patients on irbesartan. Even those with advanced disease could benefit, although the treatment is best started early on. A final study of irbesartan on diabetic patients with early signs of kidney disease showed the condition was less likely to progress than in similar patients on placebo. The trials offer new hope to people with diabetes, for there has been no treatment for kidney complications till now. They also underline the need for the earliest possible diagnosis of kidney disease in people with diabetes.


'"/>




Page: 1

Related medicine news :

1. Calcium-blocker delays atherosclerosis than beta-blockers
2. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
3. Alpha-blockers call for modification in cataract surgery
4. Advances in Treatment of Cataracts
5. Recommendations for Treatment of Blood Pressue
6. New FDA Approved Drug To Treat Migraine
7. Treatment for Menieres disease
8. Treatment for pre-menstrual syndrome is ineffective
9. Cipro Has Cheaper Cousins to Treat Anthrax
10. Better Treatment for obesity
11. Gene Treatment for Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... , ... Five consumer packaged goods (CPG) products were selected by the SupplySide ... Nopavera Plus was named to the short list in the Specialty Supplements category. ... presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort in ...
(Date:9/20/2017)... ... 2017 , ... “The Trials I Face to Receive God’s Grace”: a ... aspirations and goals to better one’s life through God. “The Trials I Face to ... all the wrong places, found a love for writing. Green feels that expressing his ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/19/2017)... ... September 19, 2017 , ... With a series of ... more than $15,000 in just a couple of weeks for those affected by ... world-class instructor seminars, organizers expect to double those initial funds with the “Submit ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: